stoxline Quote Chart Rank Option Currency Glossary
  
Vaxcyte, Inc. (PCVX)
36.57  1.295 (3.67%)    07-16 16:00
Open: 35.73
High: 36.8
Volume: 1,166,425
  
Pre. Close: 35.275
Low: 35.55
Market Cap: 4,718(M)
Technical analysis
2025-07-17 7:48:31 AM
Short term     
Mid term     
Targets 6-month :  43.97 1-year :  51.36
Resists First :  37.65 Second :  43.97
Pivot price 34.14
Supports First :  34.02 Second :  31.79
MAs MA(5) :  36.08 MA(20) :  33.97
MA(100) :  43.69 MA(250) :  73.81
MACD MACD :  0.4 Signal :  0.1
%K %D K(14,3) :  84 D(3) :  83.3
RSI RSI(14): 59.4
52-week High :  121.05 Low :  27.65
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
[ PCVX ] has closed below upper band by 12.1%. Bollinger Bands are 61.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 59 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 36.83 - 37.01 37.01 - 37.17
Low: 35.13 - 35.33 35.33 - 35.51
Close: 36.26 - 36.58 36.58 - 36.86
Company Description

Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company also develops VAX-XP to protect against emerging strains and address antibiotic resistance; VAX-A1, a conjugate vaccine candidate designed to treat Group A Strep; and VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.

Headline News

Wed, 16 Jul 2025
Mizuho Maintains an Overweight Rating on Vaxcyte (PCVX) - Yahoo Finance

Tue, 08 Jul 2025
Here’s Why Vaxcyte (PCVX) Sold Off in Q1 - Insider Monkey

Mon, 07 Jul 2025
We're Not Very Worried About Vaxcyte's (NASDAQ:PCVX) Cash Burn Rate - simplywall.st

Fri, 04 Jul 2025
Cantor Fitzgerald Maintains Overweight on Vaxcyte Amid Vaccine Development and ACIP Meeting - MSN

Mon, 30 Jun 2025
Vaxcyte, Inc.(NasdaqGS: PCVX) added to Russell 3000 Value Index - MarketScreener

Fri, 09 May 2025
Is Vaxcyte, Inc. (PCVX) The Best Stock That Will Bounce Back? - Yahoo Finance

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Outperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Neutral
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Neutral
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 129 (M)
Shares Float 116 (M)
Held by Insiders 0.6 (%)
Held by Institutions 117.6 (%)
Shares Short 13,700 (K)
Shares Short P.Month 13,490 (K)
Stock Financials
EPS -4
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 24.81
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -14.6 %
Return on Equity (ttm) -19.7 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -4.86
Qtrly Earnings Growth 0 %
Operating Cash Flow -460 (M)
Levered Free Cash Flow -419 (M)
Stock Valuations
PE Ratio -9.17
PEG Ratio 0
Price to Book value 1.47
Price to Sales 0
Price to Cash Flow -10.27
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android